ORIB · XBRL financial data

Orion Bliss financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ORIB's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Revenue	0	0	1*	0	6	9	11*	3	3	0	6*	12
General and administrative	4	7	8*	14	7	10	10*	15	10	18	10*	16
Total operating expenses	—	—	year only	—	—	—	year only	—	—	—	year only	—
Operating income (loss)	(4)	(7)	(7)*	(14)	(1)	(1)	1*	(12)	(7)	(18)	(4)*	(4)
Income tax expense (benefit)	0	0	0*	0	0	0	0*	0	0	0	0*	0
Net income (loss)	(4)	(7)	(7)*	(14)	(1)	(1)	1*	(12)	(7)	(18)	(4)*	(4)
Earnings per share, basic USD per share	0.00	0.00	0.00*	0.00	0.00	0.00	0.00*	0.00	0.00	0.00	—	0.00
Earnings per share, diluted USD per share	0.00	0.00	0.00*	0.00	0.00	0.00	0.00*	0.00	0.00	0.00	—	0.00
Weighted average shares, basic thousands of shares	3,038	3,038	3,038*	3,038	3,038	3,038	3,038*	3,038	3,038	—	—	3,038
Weighted average shares, diluted thousands of shares	3,038	3,038	3,038*	3,038	3,038	3,038	3,038*	3,038	3,038	—	—	3,038

Fiscal quarters (ORIB's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Cash and cash equivalents	1	0	0	1	6	12	0	14	14	2	0	8
Total current assets	1	0	1	1	52	55	20	14	14	2	5	8
Total assets	—	—	1	1	52	55	61	53	50	37	37	37
Total current liabilities	75	82	91	104	155	160	165	169	173	177	182	186
Accumulated deficit	(95)	(103)	(110)	(124)	(125)	(126)	(125)	(136)	(143)	(161)	(166)	(170)
Total stockholders' equity	(74)	(82)	(89)	(103)	(104)	(105)	(104)	(115)	(122)	(140)	(145)	(149)
Total liabilities and equity	1	0	1	1	52	55	61	53	50	37	37	37
Common shares outstanding (cover page) thousands of shares	3,038	3,038	3,038	3,038	3,038	3,038	3,038	3,038	3,038	3,038	3,038	3,038

Fiscal quarters (ORIB's year ends in late April)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY26Jul 31, 2025	Q2 FY26Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Apr 30, 2026	Q1 FY27Jul 31, 2026
Net income (loss)	(4)	(7)	(7)*	(14)	(1)	(1)	1*	(12)	(7)	(18)	(4)*	(4)
Net cash from operating activities	(4)*	(7)*	(7)*	(14)	45*	1*	(42)*	(6)	(2)*	(13)*	(11)*	(2)
Net cash from investing activities	—	—	0*	—	—	0*	0*	—	—	0*	0*	—
Proceeds from issuing common stock	0*	0*	0*	0	—	—	year only	—	—	—	year only	—
Net cash from financing activities	4*	7*	9*	13	6*	4*	50*	1	1*	1*	14*	4

SIC 2840 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.

How peers are chosen

SIC 2840 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Fewer than three companies fall in that range, so the list adds same-SIC (2840) companies nearest in public float, each marked “added: same SIC”.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Orion Bliss	7.6	12	(1.6)	3.0M	—	Q1 FY27 10-QJul 31, 2026
Longevity Health Holdingsadded: same SIC	35	396	(224)*	2.5M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Stepanadded: same SIC	98,092	692,154	29,341*	22.7M	—	Q3 FY26 10-QSep 30, 2026
Church & Dwightadded: same SIC	446,900	1,602,100	379,600*	236.0M	—	Q3 FY26 10-QSep 30, 2026
Ecolabadded: same SIC	722,300	4,694,800	763,700*	280.5M	—	Q3 FY26 10-QSep 30, 2026
Procter & Gambleadded: same SIC	15,365,000	23,276,000	5,767,000	2.3B	—	Q1 FY27 10-QSep 30, 2026
Bowen Acquisitionadded: same SIC	4.1	not reported	(2.9)*	2.5M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Park Ha Biological Technologyadded: same SIC	3,788	year only	year only	not reported	—	Q4 FY25 20-F/AOct 31, 2025
Unileveradded: same SIC	3,941,000	year only	year only	2.2B	—	Q4 FY25 20-FDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.